⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIIB News
Biogen Inc. Common Stock
Pre-Filled Syringes Processing Course Nov 11th - Nov 12th, 2026, Provides 12 CPD Hours on PFS Processing Fundamentals
globenewswire.com
PFE
BIIB
Neo Launches with $100M to Secure AI Software Across the Enterprise
globenewswire.com
S
PANW
SHOP
NVDA
MSFT
GOOG
AMZN
CRM
ADBE
IBM
INTC
AMD
QCOM
META
TWLO
LI
CVNA
DDOG
CRWD
OKTA
PLTR
SNOW
SMCI
MU
AMAT
LRCX
ASML
ORCL
SAP
CSCO
FTNT
CHKP
VRTX
REGN
GILD
BIIB
AZN
PFE
MRNA
BMY
AMGN
LLY
ABBV
NVO
SNPS
CDNS
MCHP
NXPI
ON
ADI
TXN
CRSP
EXAS
ALGN
TDOC
ROKU
COIN
PYPL
HOOD
Cell Viability Assays Market to Reach US$3.8 Billion by 2034 as Drug Discovery and Diagnostics Demand Accelerates
globenewswire.com
TMO
BIO
BIIB
DHR
AVTR
BDX
Duchenne Muscular Dystrophy Treatment Market Report (2025-2034) Published, Segments Intravenous, Subcutaneous, and Oral Routes Across Three Pharmacy Channels
globenewswire.com
SRPT
PFE
BIIB
REGN
GILD
JNJ
ABBV
NVS
SNY
CAPR
SLDB
WVE
EDIT
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
prnewswire.com
BIIB
Biogen Appoints Michael J. Parini as Chief Legal Officer
globenewswire.com
BIIB
Tuberculosis Clinical Trial Pipeline Shows Potential with Active Contributions from 28+ Key Companies | DelveInsight
globenewswire.com
FMS
BIIB
MDT
NVO
LLY
AZN
RDNT
LXRX
SNY
XRTX
RGEN
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
globenewswire.com
BIIB
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
prnewswire.com
BIIB
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
globenewswire.com
BIIB